| (in millions of euros) | Restructuring | Vacant property(1) | Risks and litigation | Other provisions | Total |
|---|---|---|---|---|---|
| December 31, 2023 | December 31, 2023 Restructuring 56 |
December 31, 2023 Vacant property (1)115 |
December 31, 2023 Risks and litigation 232 |
December 31, 2023 Other provisions 171 |
December 31, 2023 Total 574 |
| Increases | Increases Restructuring 20 |
Increases Vacant property (1)17 |
Increases Risks and litigation 7 |
Increases Other provisions 2 |
Increases Total 46 |
| Releases with usage | Releases with usage Restructuring (29) |
Releases with usage Vacant property (1)(15) |
Releases with usage Risks and litigation (19) |
Releases with usage Other provisions (8) |
Releases with usage Total (71) |
| Reversals without usage | Reversals without usage Restructuring (2) |
Reversals without usage Vacant property (1)– |
Reversals without usage Risks and litigation (1) |
Reversals without usage Other provisions (1) |
Reversals without usage Total (4) |
| Foreign exchange and others | Foreign exchange and others Restructuring – |
Foreign exchange and others Vacant property (1)22 |
Foreign exchange and others Risks and litigation 2 |
Foreign exchange and others Other provisions 3 |
Foreign exchange and others Total 27 |
| June 30, 2024 | June 30, 2024 Restructuring 45 |
June 30, 2024 Vacant property (1)139 |
June 30, 2024 Risks and litigation 221 |
June 30, 2024 Other provisions 167 |
June 30, 2024 Total 572 |
Restructuring
|
Vacant property (1)
|
Risks and litigation
|
Other provisions
|
Total
|
|
| December 31, 2024 | December 31, 2024 Restructuring 76 |
December 31, 2024 Vacant property (1)132 |
December 31, 2024 Risks and litigation 187 |
December 31, 2024 Other provisions 171 |
December 31, 2024 Total 566 |
| Increases | Increases Restructuring 32 |
Increases Vacant property (1)7 |
Increases Risks and litigation 1 |
Increases Other provisions 1 |
Increases Total 41 |
| Releases with usage | Releases with usage Restructuring (50) |
Releases with usage Vacant property (1)(15) |
Releases with usage Risks and litigation (5) |
Releases with usage Other provisions (5) |
Releases with usage Total (75) |
| Reversals without usage | Reversals without usage Restructuring (3) |
Reversals without usage Vacant property (1)– |
Reversals without usage Risks and litigation (9) |
Reversals without usage Other provisions – |
Reversals without usage Total (12) |
| Foreign exchange and others | Foreign exchange and others Restructuring (3) |
Foreign exchange and others Vacant property (1)(13) |
Foreign exchange and others Risks and litigation (6) |
Foreign exchange and others Other provisions (10) |
Foreign exchange and others Total (32) |
| June 30, 2025 | June 30, 2025 Restructuring 52 |
June 30, 2025 Vacant property (1)111 |
June 30, 2025 Risks and litigation 168 |
June 30, 2025 Other provisions 157 |
June 30, 2025 Total 488 |
| Of which short-term | Of which short-term Restructuring 46 |
Of which short-term Vacant property (1)26 |
Of which short-term Risks and litigation 62 |
Of which short-term Other provisions 65 |
Of which short-term Total 199 |
| Of which long-term | Of which long-term Restructuring 6 |
Of which long-term Vacant property (1)85 |
Of which long-term Risks and litigation 106 |
Of which long-term Other provisions 92 |
Of which long-term Total 289 |
(1) See note 7.
In April 2022, the Group received a notification of grievances from the Competition Authority in relation to practices implemented in the outdoor advertising sector in France. The procedure is ongoing.
On February 1, 2024, a comprehensive resolution was reached with all 50 State Attorneys General, the District of Columbia, and certain US Territories related to past work undertaken for opioid manufacturers primarily by former advertising agency Rosetta, bringing to a close, after almost three years of discussions, all complaints related to past work for opioid manufacturers—including by Rosetta (which has since merged into Publicis Health, LLC)—that could have been brought by these States and US Territories. The Attorneys General have recognized Publicis Health’s good faith and responsible corporate citizenship in reaching this resolution. In August 2024, all States and US Territories have received the settlement payment under the agreement. This settlement is in no way an admission of wrongdoing or liability.
As a reminder, on May 6, 2021, the Attorney General for the Commonwealth of Massachusetts filed a lawsuit against Publicis Health, LLC, a subsidiary of Publicis Groupe, in connection with the work that the agency and its predecessor agencies did for Purdue Pharma from 2010 to 2018 related to the marketing of opioids. The Attorney General claimed that Publicis violated the Massachusetts consumer protection statute and created a public nuisance by participating in Purdue Pharma’s efforts to market and sell opioids. This case was settled as part of a global resolution, described above, with all US States and Territories. and the District of Columbia.
On September 19, 2023, Publicis Health, LLC was named as a codefendant in a similar action brought by St. Clair County in the Court of Illinois. Publicis Health filed a motion to dismiss. This complaint is expected to be dismissed due to the resolution reached with the 50 States (including Illinois) and the existence of an “opioid bar statute” in Illinois.
On April 16, 2024, Publicis Health LLC was named as a defendant in a putative class action brought by Cleveland Bakers and Teamsters Health and Welfare Fund on behalf of itself and purportedly all other third-party payors who allegedly incurred additional costs as a consequence of the opioid epidemic. This complaint was dismissed in February 2025, and the case is closed.
In November 2024, Publicis Health LLC was named as a defendant in a similar class action brought in front of the federal court in Chicago on behalf of a group of school districts in several states (Illinois, Ohio, Maryland, New Mexico, California, Maine and New York). Publicis Health LLC denies any wrongdoing or liability and has moved to dismiss the litigation.
In February 2025, Publicis Media Canada was added to a similar opioid-related lawsuit filed in the Alberta King’s Bench Court by the City of Grande Prairie and The Corporation of the City of Brantford against 65 defendants. Publicis Media Canada has filed a motion to dismiss.
